A Phase 1 interventional study of Avapritinib in Gastrointestinal Stromal Tumors (GIST) and Other Relapsed or Refractory Solid Tumors, sponsored by Blueprint Medicines Corporation. Completed at 19 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-21.
Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Gastrointestinal Stromal Tumors with a site in United States — 19 open to participants now, 29 under way, 5 of them phase 3. Gastrointestinal Stromal Tumors · United States.
Among the 139 studies in Gastrointestinal Stromal Tumors with a site in United States, this one is the 18th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2015, is one of 32 in phase 1, and was the 90th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →19 of the 139 studies in Gastrointestinal Stromal Tumors with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Kumquat Biosciences Inc. · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
University of California, San Diego · Sites in United States
Ages 18+
GlaxoSmithKline · Sites in United States, Australia, Belgium and 16 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 63 · Phase 3 19 · Phase 4 2
First in 1997; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 55 across the 116 interventional studies, 120 across the 14 observational. Of the 105 that completed or were terminated, 49 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 139 have an industry lead sponsor. The 10 most frequent:
This study is registered under Blueprint Medicines Corporation, one of the names counted as Sanofi. Under that name alone:
Blueprint Medicines Corporation is the lead sponsor of 32 studies on the registry; 6 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 3 (21%) have results posted.
Sanofi has 5 studies filed under Gastrointestinal Stromal Tumors — fewer than ten, so there is no comparison to draw.
7 of the studies in Gastrointestinal Stromal Tumors with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01991379Memorial Sloan Kettering Cancer CenterMEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | 2026-11 |
| NCT05366816University of MiamictDNA-Guided Sunitinib And Regorafenib Therapy for GIST | 2026-12-31 |
| NCT05957367Deciphera Pharmaceuticals, LLCA Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | 2027-03 |
| NCT05489237IDRX, Inc., a wholly owned subsidiary of GSK, LLCFirst-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | 2027-03-10 |
| NCT04595747National Cancer Institute (NCI)Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 139 studies in Gastrointestinal Stromal Tumors with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR For Part 2:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.
Drug: Avapritinib
Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.
Drug: Avapritinib
Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.
Drug: Avapritinib
Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.
Drug: Avapritinib
Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation. .
Drug: Avapritinib
Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis.
Drug: Avapritinib
Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis.
Drug: Avapritinib
Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.
Drug: Avapritinib
Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis. Patients received avapritinib in continuous 28 day cycles until discontinuation.
Drug: Avapritinib
avapritinib tablets
Also known as: BLU-285
Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib
Patients with event(s) of dose-limiting toxicity
Time frame: Cycle 1 (28 days) of treatment
Parts 1 and 2: Number of Patients With Adverse Events (AE) and Serious Adverse Events (SAE)
The overall safety profile of the drug was assessed by reviewing the number of patients with AEs, SAEs and other events. There was no formal statistical analysis. Safety assessments continued for the duration of treatment.
Time frame: AEs were collected from the start of study drug until 30 days after the last dose, SAEs were collected from the date of the informed consent signature until 30 days after the last dose of study drug, up to 5 years
Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1
To evaluate objective response rate (ORR) determined by central radiology assessment per mRECIST, version 1.1 in patients with advanced GIST treated with avapritinib. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR
Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Maximum Plasma Drug Concentration (Cmax)
Maximum plasma drug concentration (Cmax) following a single dose of avapritinib
Time frame: Cycle 1 Day 1
Time to Maximum Plasma Drug Concentration (Tmax)
Cycle 1 Day 1 PK time to maximum plasma drug concentration (Tmax)
Time frame: Cycle 1 Day 1
Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose (C24)
Plasma drug concentration at 24 hours postdose prior to the next daily dose (C24) following a single dose of avapritinib
Time frame: Cycle 1 Day 1
Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC 0-24)
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC 0-24) following a single dose of avapritinib
Time frame: Cycle 1 Day 1
Apparent Oral Clearance Unadjusted for Bioavailability (CL/F)
Apparent oral clearance unadjusted for bioavailability (CL/F) following a single dose of avapritinib
Time frame: Cycle 1 Day 1
Apparent Volume of Distribution, Unadjusted for Bioavailability (Vz/F)
Apparent volume of distribution, unadjusted for bioavailability (Vz/F) following a single dose of avapritinib
Time frame: Cycle 1 Day 1
Terminal Elimination Half-life (t1/2)
Terminal elimination half-life (t1/2) following a single dose of avapritinib
Time frame: Cycle 1 Day 1
Maximum Plasma Drug Concentration (Cmax) at Steady State
Maximum plasma drug concentration (Cmax) at steady state following 15 days of QD dosing
Time frame: Cycle 1 Day 15
Time of Maximal Concentration (Tmax) at Steady State
Time of maximal concentration (Tmax) at steady state following 15 days of QD dosing
Time frame: Cycle 1 Day 15
Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at Steady State (C24,ss)
Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at steady state (C24,ss) following 15 days of QD dosing
Time frame: Cycle 1 Day 15
Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady Sate (AUC0-τ,ss) (τ=24 h)
Area under the plasma concentration-time curve over the dosing interval at steady sate (AUC0-τ,ss) (τ=24 h) following 15 days of QD dosing
Time frame: Cycle 1 Day 15
Progression-free Survival Per mRECIST Version 1.1
Progression-free survival is defined as the time in months from the start of treatment to the date of first documented progression or death due to any cause. Progression-free survival determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST), version 1.1 in patients with advanced GIST. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.
Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Apparent Oral Clearance at Steady State, Unadjusted for Bioavailability (CLss/F)
Apparent oral clearance at steady state, unadjusted for bioavailability (CLss/F) following 15 days of QD dosing
Time frame: Cycle 1 Day 15
Clinical Benefit Rate Determined by Central Radiology Assessment Per mRECIST, Version 1.1
Percent of patients with a complete response, partial response or stable disease lasting more than 16 weeks. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Stable disease is defined as a tumor that does not meet the criteria for progression or for response. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.
Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Response Rate Determined by Central Radiology Assessment Per Choi Criteria
A complete response is defined as complete disappearance of all target lesions. A partial response is ≥10% decrease tumor size at computed tomography (CT) or ≥15% decrease in tumor attenuation at computed tomography (CT) and no new lesions. The response rate is defined as complete response plus partial response.
Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Duration of Response Determined by Central Radiology Assessment Per mRECIST, Version 1.1
Duration from time to first documented CR/PR to date of first documented disease progression or death. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR
Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Median PFS on Last Prior Anti-cancer Therapy
Progression Free Survival (PFS) is defined as the time in months from the start of treatment to the date of first documented disease progression or death due to any cause, which ever occurs first. PFS on last prior anti-cancer therapy is defined as the time in months from the start of last prior anti-cancer therapy to progression on that therapy.
Time frame: Historical data collected at enrollment, all available data on prior therapy was collected
Change From Baseline in Levels of KIT and PDGFRα Mutant Allele Fractions in Peripheral Blood
Change of mutant allele fraction (MAF) summarizes the largest fold change. Change from baseline only displayed for patients with pre and post treatment MAF measurements. A positive number represents an increase in MAF. Data is only provided for patients that had both a baseline measurement and an end of treatment measurement.
Time frame: Baseline and End of treatment
KIT, PDGFRA, and Other Cancer-relevant Mutations Present in Tumor Tissue at Baseline and EOT
Change in mutations in tumor tissue at baseline and end of treatment (EOT). EOT tumor biopsies were optional and there were no EOT samples collected.
Time frame: Baseline and end of treatment
| Milestone | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD |
|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 3 | 0 |
| Patients from part 1 included in the part 2 analyses | 0 | 0 | 0 | 0 | 0 | 6 | 7 | 0 | 0 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 2 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Did not complete >21 days of treatment | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Not evaluable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 217 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 217 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 118 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Withdrew: Administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Milestone | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD |
|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 0 | 0 | 3 | 217 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 6 | 6 | 6 | 6 | 0 | 0 | 3 | 217 |
| Withdrew: Disease progression | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Death | 0 | 4 | 2 | 4 | 3 | 0 | 0 | 1 | 111 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 8 |
| Withdrew: Initiation of another therapy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Sponsor decision | 2 | 1 | 1 | 2 | 2 | 0 | 0 | 1 | 68 |
Patients with event(s) of dose-limiting toxicity
| patients with event(s) of dose-limiting | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD |
|---|---|---|---|---|---|---|---|---|
| Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
The overall safety profile of the drug was assessed by reviewing the number of patients with AEs, SAEs and other events. There was no formal statistical analysis. Safety assessments continued for the duration of treatment.
| participants | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD |
|---|---|---|---|---|---|---|---|
| Participants with an Adverse Event | 6 | 6 | 6 | 6 | 6 | 3 | 216 |
| Participants with a Serious Adverse Event | 3 | 4 | 5 | 5 | 5 | 3 | 140 |
To evaluate objective response rate (ORR) determined by central radiology assessment per mRECIST, version 1.1 in patients with advanced GIST treated with avapritinib. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR
| Participants | Patients With a PDGFRA D842V Mutation | 2L Patients Without a PDGFRA D842V Mutation | 3L Patients Without a PDGFRA D842V Mutation |
|---|---|---|---|
| Responder | 36 | 10 | 20 |
| Non-Responder | 2 | 40 | 108 |
Maximum plasma drug concentration (Cmax) following a single dose of avapritinib
| ng/mL | Part 1 Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Maximum Plasma Drug Concentration (Cmax) | 305 ± 153 | 343 ± 181 |
Cycle 1 Day 1 PK time to maximum plasma drug concentration (Tmax)
| hours | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Time to Maximum Plasma Drug Concentration (Tmax) | 4.0 (0.98 to 23.5) | 4.02 (1.97 to 24.0) |
Plasma drug concentration at 24 hours postdose prior to the next daily dose (C24) following a single dose of avapritinib
| ng/mL | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose (C24) | 134 ± 49.4 | 185 ± 80.2 |
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC 0-24) following a single dose of avapritinib
| h*ng/mL | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC 0-24) | 4510 ± 1760 | 5310 ± 2080 |
Apparent oral clearance unadjusted for bioavailability (CL/F) following a single dose of avapritinib
| L/h | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Apparent Oral Clearance Unadjusted for Bioavailability (CL/F) | 31.5 ± 15.2 | 29.9 ± 20.1 |
Apparent volume of distribution, unadjusted for bioavailability (Vz/F) following a single dose of avapritinib
| L | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Apparent Volume of Distribution, Unadjusted for Bioavailability (Vz/F) | 1310 ± 676 | 1340 ± 597 |
Terminal elimination half-life (t1/2) following a single dose of avapritinib
| h | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Terminal Elimination Half-life (t1/2) | 32.1 ± 15.6 | 43.5 ± 28.4 |
Maximum plasma drug concentration (Cmax) at steady state following 15 days of QD dosing
| ng/mL | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Maximum Plasma Drug Concentration (Cmax) at Steady State | 905 ± 402 | 1140 ± 469 |
Time of maximal concentration (Tmax) at steady state following 15 days of QD dosing
| h | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Time of Maximal Concentration (Tmax) at Steady State | 4.0 (0.0 to 8.17) | 3.99 (0.5 to 8.0) |
Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at steady state (C24,ss) following 15 days of QD dosing
| ng/mL | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at Steady State (C24,ss) | 593 ± 263 | 760 ± 343 |
Area under the plasma concentration-time curve over the dosing interval at steady sate (AUC0-τ,ss) (τ=24 h) following 15 days of QD dosing
| h*ng/mL | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady Sate (AUC0-τ,ss) (τ=24 h) | 16900 ± 7230 | 21300 ± 9250 |
Progression-free survival is defined as the time in months from the start of treatment to the date of first documented progression or death due to any cause. Progression-free survival determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST), version 1.1 in patients with advanced GIST. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.
| months | Patients With a PDGFRA D842V Mutation | 2L Patients Without a PDGFRA D842V Mutation | 3L Patients Without a PDGFRA D842V Mutation |
|---|---|---|---|
| Progression-free Survival Per mRECIST Version 1.1 | 27.6 (19.5 to NA) | 5.5 (2.0 to 9.4) | 3.7 (3.6 to 5.6) |
Apparent oral clearance at steady state, unadjusted for bioavailability (CLss/F) following 15 days of QD dosing
| L/h | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD | Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD |
|---|---|---|
| Apparent Oral Clearance at Steady State, Unadjusted for Bioavailability (CLss/F) | 21.8 ± 12.0 | 22.8 ± 11.7 |
Percent of patients with a complete response, partial response or stable disease lasting more than 16 weeks. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Stable disease is defined as a tumor that does not meet the criteria for progression or for response. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.
| Participants | Patients With a PDGFRA D842V Mutation | 2L Patients Without a PDGFRA D842V Mutation | 3L Patients Without a PDGFRA D842V Mutation |
|---|---|---|---|
| Clinical Benefit | 37 | 26 | 51 |
| No Clinical Benefit | 1 | 24 | 77 |
A complete response is defined as complete disappearance of all target lesions. A partial response is ≥10% decrease tumor size at computed tomography (CT) or ≥15% decrease in tumor attenuation at computed tomography (CT) and no new lesions. The response rate is defined as complete response plus partial response.
| Participants | Patients With a PDGFRA D842V Mutation | 2L Patients Without a PDGFRA D842V Mutation | 3L Patients Without a PDGFRA D842V Mutation |
|---|---|---|---|
| Responder | 37 | 18 | 45 |
| Non-responder | 1 | 32 | 83 |
Duration from time to first documented CR/PR to date of first documented disease progression or death. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR
| months | Patients With PDGFRA D842V Mutation | 2L Patients Without a PDGFRA D842V Mutation | 3L Patients Without a PDGFRA D842V Mutation |
|---|---|---|---|
| Duration of Response Determined by Central Radiology Assessment Per mRECIST, Version 1.1 | 22.1 (14.3 to NA) | 19.2 (9.2 to 19.2) | 10.2 (7.2 to 15.0) |
Progression Free Survival (PFS) is defined as the time in months from the start of treatment to the date of first documented disease progression or death due to any cause, which ever occurs first. PFS on last prior anti-cancer therapy is defined as the time in months from the start of last prior anti-cancer therapy to progression on that therapy.
| months | Patients With a PDGFRA D842V Mutation | 2L Patients Without a PDGFRA D842V Mutation | 3L Patients Without a PDGFRA D842V Mutation |
|---|---|---|---|
| Median PFS on Last Prior Anti-cancer Therapy | 5.9 (4.2 to 8.3) | 31.0 (26.4 to 48.0) | 6.4 (4.3 to 8.3) |
Change of mutant allele fraction (MAF) summarizes the largest fold change. Change from baseline only displayed for patients with pre and post treatment MAF measurements. A positive number represents an increase in MAF. Data is only provided for patients that had both a baseline measurement and an end of treatment measurement.
| fraction of total | Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD |
|---|---|
| Change in PDGFRA MAF | 8.702 ± NA |
| Change in KIT MAF | 14.398 ± NA |
Change in mutations in tumor tissue at baseline and end of treatment (EOT). EOT tumor biopsies were optional and there were no EOT samples collected.
No measurements were reported for this outcome.
Collected over For each patient adverse event data were collected starting at the time of the first dose of study drug until 30 days after the final dose of study drug. Serious adverse event data were collected from the time the informed consent was signed until 30 days after the final dose of study drug. On average 8 months, up to 5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | 4/6 (66.7%) | 4/6 (66.7%) | 6/6 (100%) |
| Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | 2/6 (33.3%) | 5/6 (83.3%) | 5/6 (83.3%) |
| Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | 4/6 (66.7%) | 5/6 (83.3%) | 6/6 (100%) |
| Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | 3/6 (50%) | 5/6 (83.3%) | 6/6 (100%) |
| Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD | 111/217 (51.2%) | 140/217 (64.5%) | 214/217 (98.6%) |
| Event | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD |
|---|---|---|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 1/3 | 24/217 |
| Face oedemaGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/3 | 0/217 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/3 | 0/217 |
| Mood alteredPsychiatric disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/3 | 0/217 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/3 | 0/217 |
| HypertensionVascular disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/3 | 0/217 |
| Abdominal painGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 1/6 | 0/6 | 0/3 | 8/217 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/6 | 1/6 | 0/6 | 1/6 | 1/6 | 0/3 | 4/217 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/3 | 3/217 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/3 | 4/217 |
| Event | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD |
|---|---|---|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 1/6 | 3/6 | 2/6 | 3/6 | 2/6 | 3/3 | 88/217 |
| Periorbital oedemaEye disorders | 4/6 | 4/6 | 1/6 | 4/6 | 2/6 | 1/3 | 95/217 |
| Lacrimation increasedEye disorders | 2/6 | 2/6 | 2/6 | 4/6 | 2/6 | 1/3 | 76/217 |
| DyspepsiaGastrointestinal disorders | 2/6 | 2/6 | 0/6 | 4/6 | 0/6 | 1/3 | 36/217 |
| Blood bilirubin increasedInvestigations | 1/6 | 1/6 | 1/6 | 1/6 | 0/6 | 2/3 | 48/217 |
| Weight decreasedInvestigations | 1/6 | 2/6 | 0/6 | 3/6 | 1/6 | 2/3 | 38/217 |
| DizzinessNervous system disorders | 2/6 | 1/6 | 0/6 | 2/6 | 2/6 | 2/3 | 51/217 |
| DysgeusiaNervous system disorders | 0/6 | 1/6 | 0/6 | 3/6 | 1/6 | 2/3 | 40/217 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/6 | 1/6 | 4/6 | 0/6 | 4/6 | 2/3 | 27/217 |
| Hair colour changesSkin and subcutaneous tissue disorders | 2/6 | 2/6 | 1/6 | 4/6 | 2/6 | 1/3 | 50/217 |
| Age, Continuous(years) | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 58.7 ± 12.21 | 60.2 ± 6.77 | 60.2 ± 11.84 | 61.5 ± 10.05 | 61.7 ± 8.31 | 48.3 ± 20.82 | 59.4 ± 11.00 | 59.4 ± 10.97 |
| Sex: Female, Male(Participants) | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 1 | 0 | 3 | 1 | 84 | 96 |
| Male | 2 | 3 | 5 | 6 | 3 | 2 | 133 | 154 |
| Race (NIH/OMB)(Participants) | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 1 | 0 | 0 | 1 | 0 | 0 | 10 | 12 |
| White | 5 | 6 | 4 | 5 | 4 | 3 | 154 | 181 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 2 | 0 | 28 | 32 |
| Region of Enrollment(participants) | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD | Total |
|---|---|---|---|---|---|---|---|---|
| Belgium | 0 | 0 | 1 | 1 | 1 | 0 | 13 | 16 |
| France | 0 | 0 | 1 | 1 | 2 | 0 | 20 | 24 |
| Germany | 1 | 2 | 0 | 1 | 0 | 0 | 14 | 18 |
| Netherlands | 0 | 0 | 1 | 0 | 0 | 0 | 11 | 12 |
| Poland | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 |
| South Korea | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 17 |
| Spain | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 11 |
| United Kingdom | 1 | 0 | 3 | 0 | 0 | 1 | 23 | 28 |
| United States | 4 | 4 | 0 | 3 | 3 | 2 | 100 | 116 |
| Body Mass Index (BMI)(kg/m2) | Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD | Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD | Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 24.78 ± 4.22 | 31.61 ± 8.63 | 28.33 ± 3.76 | 23.78 ± 2.71 | 24.63 ± 5.16 | 27.15 ± 4.54 | 25.98 ± 6.22 | 26.09 ± 6.15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Mar 2020, 55 months.
Results were first posted in Jun 2021, 1 year 3 months after primary completion.
Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's 55 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avapritinib
Gastrointestinal Stromal Tumors →
Blueprint Medicines Corporation →